Oruka Therapeutics (NASDAQ:ORKA) Reaches New 1-Year High – Here’s Why

Oruka Therapeutics, Inc. (NASDAQ:ORKA)’s share price reached a new 52-week high during trading on Tuesday . The stock traded as high as $105.31 and last traded at $105.14, with a volume of 872612 shares. The stock had previously closed at $98.82.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on ORKA. BTIG Research reiterated a “buy” rating and issued a $151.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday. Barclays raised their target price on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the company an “overweight” rating in a report on Monday, April 27th. Leerink Partners set a $120.00 target price on Oruka Therapeutics in a report on Thursday, April 30th. Weiss Ratings raised shares of Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th. Finally, UBS Group upped their target price on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Oruka Therapeutics has an average rating of “Moderate Buy” and an average target price of $134.30.

Oruka Therapeutics Trading Up 2.6%

The company’s 50 day moving average is $85.59 and its 200-day moving average is $61.75. The stock has a market cap of $7.11 billion, a PE ratio of -52.91 and a beta of -0.34.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). As a group, analysts forecast that Oruka Therapeutics, Inc. will post -2.25 EPS for the current year.

Insider Activity at Oruka Therapeutics

In other Oruka Therapeutics news, Director Carl Dambkowski sold 105,000 shares of the business’s stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $58.97, for a total transaction of $6,191,850.00. Following the completion of the sale, the director owned 73,743 shares in the company, valued at $4,348,624.71. The trade was a 58.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Arjun Agarwal sold 10,290 shares of the firm’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $59.07, for a total transaction of $607,830.30. Following the completion of the transaction, the senior vice president owned 16,406 shares in the company, valued at approximately $969,102.42. The trade was a 38.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 188,406 shares of company stock worth $12,019,683. 23.49% of the stock is currently owned by company insiders.

Institutional Trading of Oruka Therapeutics

Several hedge funds have recently made changes to their positions in the stock. Goldman Sachs Group Inc. bought a new position in Oruka Therapeutics in the 1st quarter worth about $2,505,000. JPMorgan Chase & Co. grew its holdings in Oruka Therapeutics by 567.7% during the second quarter. JPMorgan Chase & Co. now owns 15,425 shares of the company’s stock worth $173,000 after acquiring an additional 13,115 shares during the period. Legal & General Group Plc bought a new stake in shares of Oruka Therapeutics in the 2nd quarter worth approximately $28,000. Rhumbline Advisers bought a new position in shares of Oruka Therapeutics in the second quarter valued at $320,000. Finally, New York State Common Retirement Fund bought a new stake in shares of Oruka Therapeutics during the 2nd quarter worth $96,000. Institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.